Healthcare
Estrella Immunopharma, Inc.(ESLAW)
Live Price
Offline$0.1424
+9.54% today
1Y Change
+294.46%
Window
Jun 26, 2025 โ Jun 16, 2026
- Market Cap
- $60.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -40.0%
- Dividend Yield
- 0.0%
Coverage: 103 bars ยท Jun 26, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Estrella Immunopharma, Inc. (ESLAW) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $0.14 and up 294.5% across the available one-year price window (Jun 26, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -40.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -40.0%, free cash flow +76.6% with operating margin 0.0% and ROIC 126.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ESLAW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 3, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -40.0%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +25.0% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 3, 2026 | โ | -8.2% | +9.5% | โ |
2026 Mar 18, 2026 | +11.1% | -13.9% | +52.3% | +24.3% |
2025 Nov 12, 2025 | +30.6% | -3.8% | +13.1% | -36.0% |
Benchmark Edge
ESLAW vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ESLAW
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ESLAW Max Drawdown
-78.79%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ESLAW and SPY.
Company Overview
Estrella Immunopharma, Inc.
NASDAQ Capital Market
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
- Leadership
- Cheng Liu
- Employees
- 3
- Street Address
- 5858 Horton Street
- Mailing
- EmeryVille, CA, 94608
- Region
- EmeryVille, CA, US
- Reporting Currency
- USD
- Investor Line
- 510 318 9098
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- -40.0%
- Free Cash Flow
- +76.6%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 185.8%
- ROIC
- 126.0%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.12
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.